protein

Recombinant Human Ubiquitin Conjugating Enzyme E2D3

MBS142484

0.002 mg

140 USD

Recombinant Protein

Recombinant Human Ubiquitin Conjugating Enzyme E2D3

Ubiquitin Conjugating Enzyme E2D3

UBE2D3 Human; Ubiquitin Conjugating Enzyme E2D3 Human Recombinant; Ubiquitin-conjugating enzyme E2 D3; EC 6.3.2.19; Ubiquitin-protein ligase D3; Ubiquitin carrier protein D3; Ubiquitin-conjugating enzyme E2-17 kDa 3; E2(17)KB 3; UBC4/5; UBCH5C; MGC5416; MGC43926; UBE2D3

ubiquitin-conjugating enzyme E2 D3 isoform 1; Ubiquitin-conjugating enzyme E2 D3; ubiquitin-conjugating enzyme E2 D3; E2(17)KB 3; PRO2116; ubiquitin carrier protein D3; ubiquitin-conjugating enzyme E2(17)KB 3; ubiquitin-conjugating enzyme E2-17 kDa 3; ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homolog, yeast); ubiquitin-conjugating enzyme E2D 3 (homologous to yeast UBC4/5); ubiquitin-protein ligase D3; ubiquitin-conjugating enzyme E2D 3; Ubiquitin carrier protein D3; Ubiquitin-conjugating enzyme E2(17)KB 3; Ubiquitin-conjugating enzyme E2-17 kDa 3; Ubiquitin-protein ligase D3

UBE2D3

UBE2D3; UBE2D3; UBC4/5; UBCH5C; E2(17)KB3; UBC5C; UBCH5C

UB2D3_HUMAN

E Coli

147

Greater than 90.0% as determined by SDS-PAGE.

The UBE2D3 solution (0.25mg/ml) contains 20mM Tris-HCl buffer (pH8.0), 40% glycerol, 0.15M NaCl and 1mM DTT. Sterile filtered colorless solution.

Store at 4 degree C if entire vial will be used within 2-4 weeks. Store, frozen at -20 degree C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Avoid multiple freeze-thaw cycles.

ENZYMES; Enzymes; Ubiquitin Conjugating Enzyme

Description: UBE2D3 Human Recombinant fused with a 20 amino acid His tag at N-terminus produced in E Coli is a single, non-glycosylated, polypeptide chain containing 169 amino acids (1-149 a.a.) and having a molecular mass of 19.1kDa. The UBE2D3 is purified by proprietary chromatographic techniques. Introduction: UBE2D3 enzymes are human homologs of the yeast UBC4/5 family and play many important regulatory roles in inflammation and cancer. UbcH5a mediates the degradation of a myriad of short-lived regulatory proteins (such as p53 in the presence of E6/E6-AP or MDM2, c-Fos, I?B?, p105) and abnormal proteins. UBE2D3 has 88% and 89% sequence identity with UbcH5a and UbcH5b respectively.

4507777

NP_003331.1

NM_003340.6

P61077

16,893 Da

Activated TLR4 Signalling Pathway (106400); Adaptive Immune System Pathway (366160); Antigen Processing: Ubiquitination Proteasome Degradation Pathway (366162); BARD1 Signaling Events Pathway (137959); BMP Signalling Pathway (545370); Canonical NF-kappaB Pathway (138030); Cellular Response To Hypoxia Pathway (645259); Cellular Responses To Stress Pathway (645258); Class I MHC Mediated Antigen Processing Presentation Pathway (366161); Disease Pathway (530764)

The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of enzymes: ubiquitin-activating enzymes, or E1s, ubiquitin-conjugating enzymes, or E2s, and ubiquitin-protein ligases, or E3s. This gene encodes a member of the E2 ubiquitin-conjugating enzyme family. This enzyme functions in the ubiquitination of the tumor-suppressor protein p53, which is induced by an E3 ubiquitin-protein ligase. Multiple spliced transcript variants have been found for this gene, but the full-length nature of some variants has not been determined. [provided by RefSeq, Jul 2008]

UBE2D3: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes Lys- 11 -, as well as Lys-48 -linked polyubiquitination. Cooperates with the E2 CDC34 and the SCF(FBXW11) E3 ligase complex for the polyubiquitination of NFKBIA leading to its subsequent proteasomal degradation. Acts as an initiator E2, priming the phosphorylated NFKBIA target at positions Lys-21 and/or Lys-22 with a monoubiquitin. Ubiquitin chain elongation is then performed by CDC34, building ubiquitin chains from the UBE2D3-primed NFKBIA- linked ubiquitin. Acts also as an initiator E2, in conjunction with RNF8, for the priming of PCNA. Monoubiquitination of PCNA, and its subsequent polyubiquitination, are essential events in the operation of the DNA damage tolerance (DDT) pathway that is activated after DNA damage caused by UV or chemical agents during S-phase. Associates with the BRCA1/BARD1 E3 ligase complex to perform ubiquitination at DNA damage sites following ionizing radiation leading to DNA repair. Targets DAPK3 for ubiquitination which influences promyelocytic leukemia protein nuclear body (PML- NB) formation in the nucleus. In conjunction with the MDM2 and TOPORS E3 ligases, functions ubiquitination of p53/TP53. Supports NRDP1-mediated ubiquitination and degradation of ERBB3 and of BRUCE which triggers apoptosis. In conjunction with the CBL E3 ligase, targets EGFR for polyubiquitination at the plasma membrane as well as during its internalization and transport on endosomes. In conjunction with the STUB1 E3 quality control E3 ligase, ubiquitinates unfolded proteins to catalyze their immediate destruction. Interacts with SCF (SKP1-CUL1-F-box protein) E3 ubiquitin ligase complex; when Cullin is neddylated, the interaction between the E2 and the SCF complex is strengthened. Interacts with DAPK3. Interacts with BRCA1; the DNA damage checkpoint promotes the association with BRCA1 after ionizing radiation. Interacts non- covalently with ubiquitin. Belongs to the ubiquitin-conjugating enzyme family. 3 isoforms of the human protein are produced by alternative splicing. Protein type: Ligase; Ubiquitin ligase; Ubiquitin conjugating system; EC 6.3.2.19. Chromosomal Location of Human Ortholog: 4q24. Cellular Component: nucleoplasm; plasma membrane; endosome membrane; cytosol. Molecular Function: protein binding; ubiquitin-protein ligase activity; ATP binding; ligase activity. Biological Process: ubiquitin-dependent protein catabolic process; protein monoubiquitination; proteasomal ubiquitin-dependent protein catabolic process; transcription initiation from RNA polymerase II promoter; protein polyubiquitination; transcription, DNA-dependent; apoptosis; MyD88-independent toll-like receptor signaling pathway; protein modification process; protein ubiquitination; negative regulation of transcription from RNA polymerase II promoter; toll-like receptor 3 signaling pathway; DNA repair; BMP signaling pathway; transforming growth factor beta receptor signaling pathway; toll-like receptor signaling pathway; innate immune response; gene expression; toll-like receptor 4 signaling pathway; negative regulation of interferon type I production

0.002 mg

140 USD

0.01 mg

205

1 mg

5015